Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET
March 07 2025 - 4:01PM
Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage
biopharmaceutical company focused on developing medicines to target
hypertension, chronic kidney disease (CKD), obstructive sleep apnea
(OSA) and other diseases driven by dysregulated aldosterone, today
announced it will host a conference call and webinar to announce
topline results from its Launch-HTN and Advance-HTN pivotal trials
on Monday, March 10, 2025, at 8:00 a.m. ET.
The Launch-HTN trial evaluated the efficacy and safety of
lorundrostat, a highly selective aldosterone inhibitor, for the
treatment of uncontrolled hypertension (uHTN) or resistant
hypertension (rHTN) as an add-on therapy to an existing, prescribed
background treatment of two to five antihypertensive
medications.
The Advance-HTN trial evaluated the efficacy and safety of
lorundrostat for the treatment of uHTN or rHTN when used as an
add-on therapy to a standardized background treatment of two or
three anti-hypertensive medications.
| Monday,
March 10th@ 8:00 a.m.
ET |
|
Domestic: |
1-877-704-4453 |
| International: |
1-201-389-0920 |
| Webcast: |
Link |
A live webcast of the conference call may also be found on the
“News & Events” page in the Investor Relations section of the
Mineralys Therapeutics website.
About Mineralys TherapeuticsMineralys
Therapeutics is a clinical-stage biopharmaceutical company focused
on developing medicines to target hypertension, CKD, OSA and other
diseases driven by dysregulated aldosterone. Its initial product
candidate, lorundrostat, is a proprietary, orally administered,
highly selective aldosterone synthase inhibitor that Mineralys
Therapeutics is developing for cardiorenal conditions affected by
dysregulated aldosterone, including hypertension, CKD and OSA.
Mineralys is based in Radnor, Pennsylvania, and was founded by
Catalys Pacific. For more information, please visit
https://mineralystx.com. Follow Mineralys on LinkedIn and
Twitter.
Contact:
Investor
Relationsinvestorrelations@mineralystx.com
Media RelationsTom WeibleElixir
Health Public RelationsPhone: (1) 515-707-9678Email:
tweible@elixirhealthpr.com
Mineralys Therapeutics (NASDAQ:MLYS)
Historical Stock Chart
From Feb 2025 to Mar 2025
Mineralys Therapeutics (NASDAQ:MLYS)
Historical Stock Chart
From Mar 2024 to Mar 2025
